Current Month 2008
Article Features
  Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer
Estrogen Therapy Increases Benign Breast Disease Risk
Integrating Genetic Information with Breast Cancer Risk Factors May Help Refine Prognosis
Family Communication Impacts Attitude about Genetic Counseling/Testing for Breast Cancer
Ingredient Found In Green Tea Significantly Inhibits Breast Cancer Growth In Female Mice
Screening Mammography in Elderly Patients Beneficial
Human Breast Tumor Microenvironment Primes it for Metastasis
MRI Changes Breast Cancer Treatment Choice, Increases Time to Treatment
Randomized Clinical Trial Results on Preoperative Chemotherapy in Early Breast Cancer
Breast Cancer More Aggressive Among Obese Women
Obesity May Keep Some Women from Getting Screened for Breast and Cervical Cancers
Lack of Patient-Provider Discussion Contributes to Disparities in Use of Breast Reconstruction
Radiation Beneficial for Older Breast Cancer Patients
Eating Soy Foods in Puberty May Protect Against Breast Cancer
A Diagnosis of Triple-Negative Breast Cancer Doesn’t Always Mean Cancer Spread

Hormone Replacement Therapy Increases Recurrence in Breast Cancer Survivors

Hormone replacement therapy (HRT) for peri- and postmenopausal symptoms increases disease recurrence in breast cancer survivors, according to an article published in the Journal of the National Cancer Institute.

Previous studies have shown that HRT increases breast cancer incidence in healthy women, but its impact on breast cancer survivors has remained obscure. Observational studies and one small randomized trial had suggested that HRT had no effect or even might reduce recurrence. However, two-year follow-up data from the randomized HABITS (Hormonal Replacement After Breast Cancer -Is It Safe?) trial indicated that survivors who took HRT were more likely to suffer disease recurrence than those who did not take HRT.

In the current analysis, Lars Holmberg, M.D., Ph.D., currently at King's College London and colleagues examined the breast cancer rates for women in the HABITS trial after a median follow-up of four years.

At the time of this analysis, 39 (17.6 percent) of the 221 women in the HRT treatment arm had developed breast cancer recurrence or a new breast cancer malignancy, compared with 17 (7.7 percent) of 221 women in the control arm. The estimated 5-year cumulative rate for disease recurrence was 22.2 percent for the HRT arm and 9.5 percent in the control arm, for an absolute increase in risk of 14.2 percent.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon